Professor Francque is a renowned expert in the field of nonalcoholic fatty liver disease (NAFLD) and its advanced form, Metabolic Dysfunction-Associated Steatohepatitis (MASH).

He has a long-standing interest and expertise in NAFLD and MASH, with research focusing on the vascular changes in steatosis and their contribution to disease progression.  Genflow stands to gain significant value from Professor Francque’s extensive knowledge of MASH, particularly in identifying new targets and potential therapies for the disease.

Moreover, Professor Francque’s expertise in clinical research and clinical trial design will be invaluable in the development of clinical trial programs for the Company’s novel therapeutics. His membership on the SAB will play a vital role in shaping and brodeaning the Company’s strategy and direction, and his vast experience will be integral to achieving the Company’s goal of improving the lives of patients with MASH.